Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Dr Patrick Burnett on Shared Decision-Making for Moderate to Severe Psoriasis

September 17th 2022, 5:40pm

Video

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses clinical recommendations for patients with moderate to severe psoriasis, particularly the need for shared decision-making.

Study Highlights Wide Variation in Mortality of Spondyloarthritis, IBD Across the Globe

September 13th 2022, 2:15pm

Article

The study also found that over a decade, death rates did not change significantly for ankylosing spondylitis but decreased for inflammatory bowel disease (IBD).

Dr Patrick Burnett Discusses Efficacy, Safety Profile of Roflumilast Cream in Psoriasis

September 10th 2022, 3:40pm

Video

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks on the positive safety and efficacy profile shown in the DERMIS-1 and DERMIS-2 trials exploring use of roflumilast cream in patients with chronic plaque psoriasis, including those with intertriginous disease.

Researchers Outline Treatment Options for Nail Psoriasis, Other Common Nail Disorders

September 9th 2022, 3:30pm

Article

Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.

Psoriasis May Lower Pneumonia Risk in Patients With ESRD

August 30th 2022, 11:33am

Article

A decade’s worth of retrospective data from over 1 million patients with end-stage renal disease (ESRD) undergoing dialysis showed that psoriasis may be protective against pneumonia in these patients.

Dr Patrick Burnett Explains Mechanism of Action for Roflumilast Cream in Psoriasis

August 25th 2022, 12:10pm

Video

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the mechanism of action for roflumilast cream, the only phosphodiesterase-4 inhibitor approved by the FDA for the treatment of plaque psoriasis in patients aged 12 and older.

TNF Inhibitors Linked to Higher Risk of Psoriasis in Patients With IBD, RA

August 16th 2022, 10:30pm

Article

While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).

Study Suggests Causal Link Between Psoriasis, Cardiovascular Disease

August 14th 2022, 12:55pm

Article

The findings add to previous research on similar outcomes between psoriasis and cardiovascular disease, using a Mendelian randomization study.

Dr Patrick Burnett on Clinical Research Needs, Awareness of Intertriginous Psoriasis

August 13th 2022, 1:10pm

Video

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis.

Plaque Psoriasis Itching May Impact HRQOL Even if Condition Improves

August 10th 2022, 7:35pm

Article

The real-life findings showed that treatment with brodalumab improved health-related quality of life (HRQOL) for patients but itching prevented complete improvement.